Autologous haematopoietic stem cell transplantation (AHSCT) is a multistep procedure that
enables destruction of the immune system and its reconstitution from haematopoietic stem …

Abstract Treatment of multiple sclerosis (MS) is challenging: disease-modifying treatments
(DMTs) must both limit unwanted immune responses associated with disease initiation and …

These updated EBMT guidelines review the clinical evidence, registry activity and
mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple …

Background Strong immunosuppression, including chemotherapy and immune-depleting
antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has …

Objective: To assess in multiple sclerosis (MS) the effect of intense immunosuppression
followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone …

The availability of multiple disease-modifying medications with regulatory approval to treat
multiple sclerosis illustrates the substantial progress made in therapy of the disease …

Importance Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who receive
approved disease-modifying therapies experience breakthrough disease and accumulate …

Multiple sclerosis (MS) is a central nervous system (CNS) disorder, which is mediated by an
abnormal immune response coordinated by T and B cells resulting in areas of inflammation …

Background Autologous haematopoietic stem cell transplantation (HSCT) is a viable option
for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been …

Autologous haematopoietic stem cell transplantation (HSCT) is the only treatment that is
able to induce long-term, drug-free and symptom-free remission in several refractory …